Skip to main
DMRA

Galecto Inc (DMRA) Stock Forecast & Price Target

Galecto Inc (DMRA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Damora Therapeutics is well-positioned to address the crucial medical need for disease-modifying treatments for MPNs through its promising pipeline of biologics, including DMR-001, which has shown positive results in Phase 1 trials. With strong potential to expand its target market beyond Type 1 mutations, the company has a competitive advantage over other treatments in development. The recent failure of a competing treatment further emphasizes the potential for DMR-001 to stand out in the market and secure a strong market share.

Bears say

Damora Therapeutics is a pre-commercial biotechnology company with a promising pipeline of potential treatments for hematologic disorders driven by mutant calreticulin. However, there are still several key risks associated with the company, including clinical, regulatory, and commercial challenges for its lead drug candidate DMR-001. Additionally, competition from larger biotech companies with similar treatments and potential setbacks in clinical trials could impact the company's timeline for bringing its drugs to market. Overall, while Damora has a strong potential in the lucrative essential thrombocythemia market, its success is not guaranteed and carries significant risks for investors.

Galecto Inc (DMRA) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Galecto Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Galecto Inc (DMRA) Forecast

Analysts have given Galecto Inc (DMRA) a Buy based on their latest research and market trends.

According to 4 analysts, Galecto Inc (DMRA) has a Buy consensus rating as of Jul 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Galecto Inc (DMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.